Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Phio Pharmaceuticals Corp (NQ: PHIO ) 2.230 -0.120 (-5.11%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Phio Pharmaceuticals Corp Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) November 07, 2024 Marlborough, Massachusetts--(Newsfile Corp. - November 7, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company creating new... Via Newsfile Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series November 01, 2024 Marlborough Massachusetts--(Newsfile Corp. - November 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company creating new... Via Newsfile Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) October 24, 2024 Marlborough, Massachusetts--(Newsfile Corp. - October 24, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary... Via Newsfile Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series October 18, 2024 Marlborough, Massachusetts--(Newsfile Corp. - October 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary... Via Newsfile Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series October 18, 2024 Marlborough, Massachusetts--(Newsfile Corp. - October 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary... Via Newsfile Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference October 16, 2024 PH-894: Potent and Specific Silencing of BRD4 in NK CellsMarlborough, Massachusetts--(Newsfile Corp. - October 16, 2024) - Phio Pharmaceuticals Corp.... Via Newsfile Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells October 07, 2024 INTASYL compounds also improve the functionality and outcomes of adoptive cell therapies such as NK, TIL and CAR-TMarlborough, Massachusetts--(Newsfile Corp.... Via Newsfile Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series October 02, 2024 Presentation and live Q&A to take place Wednesday, October 9, 2024, at 2 PM EDTMarlborough, Massachusetts--(Newsfile Corp. - October 2,... Via Newsfile Phio Pharmaceuticals Announces Upcoming Presentation at ASGCT's 2024 Advancing Gene + Cell Therapies for Cancer Conference October 01, 2024 Marlborough, Massachusetts--(Newsfile Corp. - October 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary... Via Newsfile INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society September 25, 2024 Marlborough, Massachusetts--(Newsfile Corp. - September 25, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary... Via Newsfile Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series September 17, 2024 Presentation and live Q&A to take place Tuesday, September 24, 2024, at 12 PM EDTMarlborough, Massachusetts--(Newsfile Corp. - September 17,... Via Newsfile Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA September 16, 2024 Phio's INTASYL self-delivering RNAi technology enhances cell potency and yield in Adoptive Cell Therapy Marlborough, Massachusetts--(Newsfile Corp. - September... Via Newsfile Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 09, 2024 Conference to be held in New York City September 9-11thMarlborough, Massachusetts--(Newsfile Corp. - September 9, 2024) - Phio Pharmaceuticals Corp.... Via Newsfile Topics Intellectual Property Exposures Intellectual Property Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series August 29, 2024 Marlborough, Massachusetts--(Newsfile Corp. - August 29, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary... Via Newsfile Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update August 14, 2024 Marlborough, Massachusetts--(Newsfile Corp. - August 14, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary... Via Newsfile Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio's Patented INTASYL Compound August 06, 2024 Marlborough, Massachusetts--(Newsfile Corp. - August 6, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary... Via Newsfile Topics Intellectual Property Exposures Intellectual Property Phio Pharmaceuticals Announces New Chief Financial Officer August 01, 2024 Marlborough, Massachusetts--(Newsfile Corp. - August 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary... Via Newsfile Topics Initial Public Offering Exposures Securities Market Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds July 12, 2024 Marlborough, Massachusetts--(Newsfile Corp. - July 12, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) (the "Company"), a clinical stage biotechnology company... Via Newsfile Topics Regulatory Compliance Exposures Legal Regulatory Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762 July 08, 2024 Five sites across the U.S. are now participating in the Phase 1b study Marlborough, Massachusetts--(Newsfile Corp. - July 8,... Via Newsfile Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds July 05, 2024 Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary... Via Newsfile Phio Pharmaceuticals Announces Reverse Stock Split July 02, 2024 Marlborough, Massachusetts--(Newsfile Corp. - July 2, 2024) - Phio Pharmaceuticals Corp. (Nasdaq: PHIO) (the "Company"), a clinical stage biotechnology company... Via Newsfile Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging June 18, 2024 Phio's Compound RXI-185 is designed to slow progression of UV induced collagen breakdownMarlborough, Massachusetts--(Newsfile Corp. - June 18, 2024) -... Via Newsfile Topics Intellectual Property Exposures Intellectual Property Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762 May 28, 2024 Intratumoral PH-762 has encouraging safety profile in the initial cohortEscalation to proceed to next dose concentrationMarlborough, Massachusetts--(Newsfile Corp. - May... Via Newsfile Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) May 23, 2024 Marlborough, Massachusetts--(Newsfile Corp. - May 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary... Via Newsfile Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update May 09, 2024 From Phio Pharmaceuticals Corp. Via GlobeNewswire Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update April 02, 2024 From Phio Pharmaceuticals Corp. Via GlobeNewswire Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update November 09, 2023 From Phio Pharmaceuticals Corp. Via GlobeNewswire Phio Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update August 10, 2023 From Phio Pharmaceuticals Corp. Via GlobeNewswire Phio Pharmaceuticals Corp. (NASDAQ: PHIO) Near the Top of Equities by Percentage Gain on 4/18 April 18, 2023 Via Investor Brand Network Why Pharmaceutical Companies in Ovarian Cancer Drugs Market are Betting Big on R&D September 17, 2021 Via FinancialNewsMedia Topics Death Exposures Death Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
